Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD

Bone Marrow Transplantation

Volumn 47, Issue 5, 2012, Pages 747-748

  Pidala, J ^a,b   Perez, L ^a,b   Beato, F ^a   Anasetti, C ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PSORALEN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE; USTEKINUMAB; VISILIZUMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; APLASTIC ANEMIA; CASE REPORT; CD4+ T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; FEMALE; GLUCOCORTICOID REFRACTORY ACUTE GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LETTER; LYMPHOCYTE DIFFERENTIATION; PATHOGENESIS; PRIORITY JOURNAL; PUVA; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL;

ADULT; ANTIBODIES, MONOCLONAL; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HUMANS; PROTEINS;

EID: 84860888650     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.172     Document Type: Letter

References (10)

1. Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009; 114: 3101-3112.
2. Williamson E, Garside P, Bradley JA, More IA, Mowat AM. Neutralizing IL-12 during induction of murine acute graftversus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J Immunol 1997; 159: 1208-1215.
3. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 2009; 113: 1365-1374.
4. Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C et al. helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: 170-178.
5. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C et al. IL-17 contributes to CD4-mediated graft-versushost disease. Blood 2009; 113: 945-952.
6. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease. Blood 2009; 113: 2352-2362.
7. Paczesny S, Hanauer D, Sun Y, Reddy P. New perspectives on the biology of acute GVHD. Bone Marrow Transplant 2010; 45: 1-11.
8. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25: 139-170.
9. Williamson E, Garside P, Bradley JA, Mowat AM. IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol 1996; 157: 689-699.
10. Yang YG. The role of interleukin-12 and interferon-gamma in GVHD and GVL. Cytokines Cell Mol Ther 2000; 6: 41-46.